This is yet more reason Biopharma Manufacturing needs to be restructured. Since there isn’t a cure and those who seem to beat the challenge and create one are either threatened or have their labs burned down, this is a wake-up call: “Smart Manufacturing of specialized medicines is not just an option but a necessity.” Imagine today: in Biopharma manufacturing, production takes 12-18 months, small-batch medicines are very expensive, and bottlenecks never cease. This is where @MustardBio comes in. Mustard is a deeptech lifesciences startup building an AI-native autonomous manufacturing ecosystem that turns raw materials into finished batches of medicines with minimal human intervention. Our goal is to apply the “Dark Factory” concept, a vertically integrated manufacturing architecture we designed from the ground up to autonomously control machines, orchestrate processes, and unify quality assurance, maintenance, compliance, and supply chain management into one intelligent software, to achieve 10x faster production and up to 30x lower costs, enabling affordable, accessible medicines globally. Our “Factory OS” controls two hardware forms: 1. A smart factory hub for mass production: a large-scale, renewable-powered facility running on proprietary software for high-volume medicines at scale. 2. Mobile mini-factories: easily deployed, renewable-energy-powered, containerized manufacturing pods for low-cost, small-batch, rapid supply at the point of need (e.g., clinical trial sites, pandemic control centers, research labs, and hospitals).